Adam Feuerstein actually chimed in on the SA article
"Roche will be deeply involved the upcoming (sometime in 2012) Phase II trial and is very likely to have followed the previous Phase II trial closely as well." Per Adam F.:
"That is wrong.
If you'd bother to ask Roche/Genentech about the phase II trial of Nuevax and Herceptin, here's what you'd learn:
"T-DM1, pertuzumab and subcu Herceptin are the focus for Roche. We're providing funding and drug for a small IST [investigator-sponsored trial], but it is not the focus of the Roche strategy," says Genentech spokesman Ed Lang. "
While it was sort of a "you are wrong, checkmate" to the author, it still validates the funding to a small IST. It probably sends a message no buyout will occur in the nearterm (which I am ok with); however, Roche is funding that project. Hard to say this is a scam...